Benitec Biopharma Inc. (BNTC)
Largest Insider Buys in Sector
BNTC Stock Price History Chart
BNTC Stock Performance
About Benitec Biopharma Inc.
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Insider Activity of Benitec Biopharma Inc.
Over the last 12 months, insiders at Benitec Biopharma Inc. have bought $1.35M and sold $0 worth of Benitec Biopharma Inc. stock.
On average, over the past 5 years, insiders at Benitec Biopharma Inc. have bought $673,499 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SUVRETTA CAPITAL MANAGEMENT, LLC () — $1.35M.
The last purchase of 20,018 shares for transaction amount of $225,203 was made by SUVRETTA CAPITAL MANAGEMENT, LLC () on 2024‑12‑24.
List of Insider Buy and Sell Transactions, Benitec Biopharma Inc.
| 2024-12-24 | 20,018 0.0838% | $11.25 | $225,203 | 0.00% | ||||
| 2024-12-23 | 27,502 0.1165% | $10.98 | $301,972 | +6.76% | ||||
| 2024-12-03 | 42,000 0.1737% | $9.60 | $403,200 | +17.70% | ||||
| 2024-11-20 | 27,436 0.113% | $10.22 | $280,396 | +5.44% | ||||
| 2024-11-19 | 14,000 0.0584% | $9.73 | $136,220 | -2.16% | ||||
| 2023-08-11 | director | 51,813 <0.0001% | $0.00 | $5 | +26.33% | |||
| 2023-08-11 | Executive Director | 25,907 <0.0001% | $0.00 | $3 | +26.33% |